JNCCN 360 - Non-Small Cell Lung Cancer

Editor:

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

Roy S. Herbst, MD, PhD, on Osimertinib for NSCLC: Clinical Implications of a Potentially Practice-Changing Finding

Egbert F. Smit, MD, PhD, on Clinical Implications of Fam-trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Julia K. Rotow, MD, on Concurrent Osimertinib Plus Gefitinib in First-Line Treatment of NSCLC

Recent

WCLC 2020: Adding Sintilimab to Chemotherapy for Nonsquamous NSCLC

Phase I Trial of Combined MEK and EGFR Inhibition in NSCLC

COVID-19 and Lung Cancer: Proactive Measures for Screening Patients

Osimertinib Given Breakthrough Therapy Designation for EGFR-Mutated Lung Cancer

Published

Medical Literature

Advanced NSCLC: Tepotinib for MET Exon 14 Skipping Mutation

First-line Osimertinib and Bevacizumab Treatment in Metastatic EGFR-Mutant Lung Cancer

Third-Generation EGFR Tyrosine Kinase Inhibitor in Lung Cancer

Pneumonitis in Patients Treated With Chemotherapy or Immunotherapy

Ongoing

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Lung Cancer

Time to Tailor NSCLC RT to Spare the Immune System?

Visiting Professors: Lung Cancer Edition, Issue 1, 2019

Available

Clinical Trials

Huntsman Cancer Institute at the University of Utah

Fred and Pamela Buffett Cancer Center

Roswell Park Cancer Institute

UC San Diego Moores Cancer Center

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.